Give the most personal gift you can give—DNA discovery.
23andMe plus Registered Membership
Give them an annual membership that includes access to new premium reports and features throughout the year.
- Includes everything from our Health plus Ancestry kit
- PLUS access to exclusive reports that help them learn about their heart health, how you process certain medications**Learn about Considerations and Limitations for Pharmacogenetics Reports, migraine, and more
- Enhanced ancestry features
- Learn more
Health plus Ancestry Service
Give them essential DNA insights into their health like type 2 diabetes and muscle composition.
- Includes everything from our Ancestry plus Traits kit
- Plus 65+ health reports and features
- Includes FDA-authorized reports
- Learn more
Compare all gifts.
|Feature||Ancestry plus Traits Service||Health plus Ancestry Service|
Ancestry plus Traits
|DNA Relative Finder|
Opt in to connect and message with people who share DNA with you.
Learn how your DNA influences your facial features, taste, smell and other traits.
|Health Predisposition reports*Learn about Considerations and Limitations for Health Predispositions Reports, Carrier Status Reports and Genetic Health Risks|
Learn how your genetics can influence your chances of developing certain health conditions.
|Carrier Status reports*Learn about Considerations and Limitations for Health Predispositions Reports, Carrier Status Reports and Genetic Health Risks|
If you are starting a family, find out if you are a carrier for certain inherited conditions.
Learn how your genes play a role in your well-being and lifestyle choices.
|Family Health History Tree|
Easily input, track and download your family health history to share with your healthcare provider.
|Pharmacogenetics reports**Learn about Considerations and Limitations for Pharmacogenetics Reports|
Discover how your DNA may impact how your body processes certain medications with three new Pharmacogenetics reports.
|Enhanced ancestry features|
Get advanced filtering for DNA Relative Finder and access up to 5000 more DNA relatives.
|Ongoing new reports and features|
Get access to new premium reports and features throughout the year.
Frequently Asked Questions
Standard and Express shipping methods are available. Standard orders are shipped through Canada Post. Express orders are shipped through Purolator. Here are expected delivery timeframes from the date of shipment:
- Standard: delivery within 5-8 business days
- Express: delivery within 2-3 business days
Reports will be available through a secure, online account at 23andme.com in approximately 3-4 weeks.
Stay in the know.
Keep up-to-date with new discoveries and exclusive promotions on our DNA testing kits and services.
*23andMe health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/
**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Results for SLCO1B1 and DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetics reports, visit 23andme.com/test-info/pharmacogenetics/